United Drug trading profit up 14%
ISEQ-listed United Drug has reported a 14% increase in trading profit for the six months ending March 31, 2006, over the same period last year.
Group revenue was up from €634m to €708m, an increase of 12%.
Pre-tax profits were up 15%, from €22m to €25.3m.
The group attributes its record performance for the period to strong performances from its four business divisions and the successful integration of three UK acquisitions.
Chief executive Liam FitzGerald said: “The first six months of our 2006 year has seen a continuation of our track record of delivering double-digit profit and earnings growth.
“This period has also seen important developments with the completion of the integration of a number of our businesses into enlarged and state-of-the-art facilities that will aid the future growth of those businesses.
“The three bolt-on UK acquisitions completed in the second half of our 2005 financial year have been brought fully into the group and are adding value to our service offering.
“The continuing implementation of our strategy over the last six months positions us well for the remainder of this year and for the years ahead.”
